ProstaScint (Cytogen Corp)

ProstaScint (Cytogen Corp) - General Information

Murine IgG1 monoclonal antibody 7E11-C5.3 antibody conjugated to linker chelator peptide group for indium attachment

 

Pharmacology of ProstaScint (Cytogen Corp)

Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors

 

Additional information about ProstaScint (Cytogen Corp)

ProstaScint (Cytogen Corp) Indication: For diagnosis of prostate cancer and detection of intra-pelvic metastases
Mechanism Of Action: Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Capromab
Synonyms: ProstaScint; Capromab pendetide
Drug Category: Imaging Agents
Drug Type: Biotech; Approved

Other Brand Names containing Capromab: ProstaScint (Cytogen Corp);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production
Half Life: Not Available
Dosage Forms of ProstaScint (Cytogen Corp): Not Available
Chemical IUPAC Name: Murine anti-7E11 antibody
Chemical Formula: Not Available
Capromab on Wikipedia: https://en.wikipedia.org/wiki/Capromab
Organisms Affected: Humans and other mammals